Why we measure it

HDL particles perform reverse cholesterol transport — they extract cholesterol from arterial walls and peripheral tissues and return it to the liver for excretion or recycling. ApoA-I is not merely structural; it is functionally active in this process, directly interacting with the ABCA1 transporter that initiates cholesterol efflux from cells. A higher ApoA-I concentration generally reflects a larger atheroprotective particle capacity. The ApoB/ApoA-I ratio — measured from the same blood draw — combines both sides of the cardiovascular risk equation: atherogenic particle burden (ApoB) versus atheroprotective particle count (ApoA-I). Multiple large studies have established it as a more powerful predictor of cardiovascular risk than the standard total cholesterol/HDL-C ratio, LDL-C alone, or either apolipoprotein alone. The INTERHEART Study (Yusuf et al., Lancet 2004), a case-control analysis of myocardial infarction in 52 countries involving 29,972 participants, found that the ApoB/ApoA-I ratio was the single strongest lipid-related risk factor for myocardial infarction across all regions and ethnic groups studied — outperforming the conventional lipid panel in predictive value. Jungner and Walldius, whose work over decades established the clinical utility of apolipoproteins, demonstrated in a prospective study of over 175,000 Swedish adults that ApoB/ApoA-I outperformed all other lipid ratios in predicting fatal myocardial infarction.

Why every 3 months

ApoA-I responds to diet, physical activity, alcohol intake, smoking, and metabolic state on a timescale of weeks to months — comparable to ApoB. Regular aerobic exercise is one of the most consistent ways to raise ApoA-I. Conversely, central adiposity, insulin resistance, and hypertriglyceridaemia tend to lower functional HDL particle count and ApoA-I. Quarterly tracking allows you to see whether lifestyle changes are shifting the balance between atherogenic and atheroprotective particles — a more complete cardiovascular risk picture than tracking either alone.

What movement means

There are no universally adopted clinical guideline thresholds for ApoA-I equivalent to the ESC/EAS targets for ApoB. The 2019 ESC/EAS Guidelines note that ApoA-I can be used as an alternative to HDL-C and that the ApoB/ApoA-I ratio provides useful additional information, but specific numerical targets are not defined by the guidelines for ApoA-I in isolation. The values below reflect laboratory reference ranges and distributions observed in large population studies.

In the protocol